Stifel Nicolaus reiterated their buy rating on shares of Gilead Sciences Inc. (NASDAQ:GILD) in a report issued on Wednesday morning. The brokerage currently has a $100.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on the company. Leerink Swann reiterated a market perform rating and issued a $89.00 price target on shares of Gilead Sciences in a research report on Tuesday, November 15th. Jefferies Group restated a buy rating on shares of Gilead Sciences in a research report on Tuesday, November 8th. Mizuho started coverage on Gilead Sciences in a research report on Monday, November 7th. They set a buy rating and a $88.00 target price for the company. Zacks Investment Research upgraded Gilead Sciences from a strong sell rating to a hold rating in a research report on Monday, November 7th. Finally, Maxim Group restated a hold rating on shares of Gilead Sciences in a research report on Sunday, November 6th. Ten analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $97.90.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences (NASDAQ:GILD) opened at 73.70 on Wednesday. The stock has a 50 day moving average price of $74.54 and a 200 day moving average price of $80.07. The firm has a market cap of $97.10 billion, a PE ratio of 6.81 and a beta of 1.25. Gilead Sciences has a 52 week low of $71.39 and a 52 week high of $108.31.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.87 by $0.12. The company earned $7.40 billion during the quarter, compared to analysts’ expectations of $7.47 billion. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. Gilead Sciences’s revenue for the quarter was down 9.6% compared to the same quarter last year. During the same quarter last year, the firm posted $3.22 earnings per share. Equities analysts expect that Gilead Sciences will post $11.47 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Financial Market News and is the sole property of of Financial Market News. If you are viewing this story on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The legal version of this story can be viewed at http://www.financial-market-news.com/gilead-sciences-inc-gild-given-buy-rating-at-stifel-nicolaus/1212466/.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 29th. Investors of record on Thursday, December 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, December 13th. This represents a $1.88 annualized dividend and a yield of 2.55%. Gilead Sciences’s dividend payout ratio is currently 17.44%.

In other Gilead Sciences news, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $74.86, for a total value of $7,860,300.00. Following the completion of the sale, the director now owns 121,761 shares of the company’s stock, valued at $9,115,028.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider John C. Martin sold 100,000 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $77.63, for a total transaction of $7,763,000.00. Following the completion of the sale, the insider now directly owns 3,231,096 shares of the company’s stock, valued at approximately $250,829,982.48. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in GILD. Capital Research Global Investors increased its stake in shares of Gilead Sciences by 9.7% in the third quarter. Capital Research Global Investors now owns 27,886,530 shares of the biopharmaceutical company’s stock valued at $2,206,382,000 after buying an additional 2,474,271 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Gilead Sciences by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 26,786,930 shares of the biopharmaceutical company’s stock valued at $2,119,382,000 after buying an additional 169,701 shares in the last quarter. BlackRock Fund Advisors increased its stake in Gilead Sciences by 6.8% in the third quarter. BlackRock Fund Advisors now owns 26,032,555 shares of the biopharmaceutical company’s stock valued at $2,059,696,000 after buying an additional 1,663,268 shares in the last quarter. Capital World Investors increased its stake in Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock valued at $1,277,907,000 after buying an additional 3,380,000 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in Gilead Sciences by 17.0% in the second quarter. Alliancebernstein L.P. now owns 13,346,714 shares of the biopharmaceutical company’s stock valued at $1,113,383,000 after buying an additional 1,942,138 shares in the last quarter. 73.59% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.